Coronary/Structural Heart

First Patient Enrolled in AMIHOT III Trial Investigating ZOLL’s Supersaturated Oxygen Therapy in Heart Attack Patients

Study Evaluates the Effectiveness of TherOx Supersaturated Oxygen (SSO2) Therapy in Patients Presenting with Acute Anterior Myocardial Infarction with Successful Reperfusion Compared to Standard Therapy CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the first patient has enrolled in […]

Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction

– Completed Second Cohort Showed an Average 30% Relative Increase in Ejection Fraction (EF) at 90 Days Following a Single Administration of JK07 – – Cohort 3 Sentinel Subject Demonstrated a >70% Relative EF Increase at Day 30 – – Company also Announces the First CTA Approval for JK08, the First […]

Treatment of Severe Heart Failure – AI: FineHeart certified ISO 13485 : 2016 for Medical Device Quality Management Systems

ICOMS FLOWMAKER®, First Fully Implantable Electro-Physiological Cardiac Assistance Device September 07, 2022 08:44 AM Eastern Daylight Time BORDEAUX, France–(BUSINESS WIRE)–FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, […]

Covid-19 Pandemic Boosts Adoption of Remote Patient Monitoring in Cardiac Rehab, Survey Finds

Survey of cardiac rehab clinicians finds that over half started using RPM within just the last two years Campbell, Calif. – September 7, 2022 – Vivalink, a leading provider of digital healthcare solutions, today announces the results of its survey of cardiac rehabilitation clinicians and their insights into the current […]

Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced clearance of its Investigational New Drug (IND) application to begin clinical testing of […]

Internationally Renowned Clinician and Researcher Named Director of Interventional Cardiology at NYU Langone Health

NEW YORK, Sept. 1, 2022 /PRNewswire/ — Sunil V. Rao, MD, one of the world’s premier clinician-investigators in the field of interventional cardiology, has been named director of interventional cardiology at NYU Langone Health and the director of the cardiac catheterization laboratory at the Manhattan campus of NYU Langone. Dr. Rao, who will also […]

Viz.ai Receives FDA 510(k) Clearance for Automated RV/LV Analysis Algorithm

Part of the Viz PE Solution, new algorithm flags key patient risk indicator of pulmonary embolism severity SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an automated RV/LV ratio algorithm, a seamless […]

i-Cordis Receives SBIR Phase II Funding to Develop Treatment for Heart Failure with Preserved Ejection Fraction

BALTIMORE, Sept. 1, 2022 /PRNewswire/ — i-Cordis, LLC, an early-stage pharmaceutical company, has been awarded a Phase II Small Business Innovation Research (SBIR) grant for $1,548,708 from the National Heart, Lung, and Blood Institute (NHLBI) to further develop a potential immune-modulatory treatment for Heart Failure with preserved Ejection Fraction (HFpEF). HFpEF is one of […]

Venus Medtech announces 2022 interim results: quality and efficiency improvement, profitability focus, rapid progress in global presence

HANGZHOU, China, Sept. 1, 2022 /PRNewswire/ — On August 31, 2022, Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as “Venus Medtech”), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced its interim results for the six months ended June 30, 2022. Under repeated COVID-19 outbreaks, Venus Medtech intensified its […]